CliffBio
small molecule

RAXAR

GREPAFLOXACIN HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyOtsuka Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameRAXAR
Active ingredientGREPAFLOXACIN HYDROCHLORIDE
StrengthEQ 200MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 1997
Marketing statusDISCN

More from Otsuka Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.